Payment overview · 2025
General Payments
$1,512.74
59 reported records · 29 companies
Healthcare provider profile · identity verified
Melissa Sheppard, AGPCNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · AURORA, CO · NPI 1548023120
Verified facts
What the public records show
CMS Open Payments records show Melissa Sheppard, AGPCNP-BC received $1,512.74 in general payments during 2025 across 59 reported records.
Janssen Biotech, Inc. accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $201.53 | 13.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.91 | 10.2% | 7 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $122.59 | 8.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.96 | 6.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.99 | 5.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.07 | 5.1% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $71.52 | 4.7% | 3 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.35 | 4.7% | 3 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $50.64 | 3.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $48.07 | 3.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $47.56 | 3.1% | 2 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $35.05 | 2.3% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $35.01 | 2.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.74 | 2.2% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $32.67 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.65 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.18 | 2.0% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $29.63 | 2.0% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $28.82 | 1.9% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.75 | 1.9% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $28.02 | 1.9% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $26.51 | 1.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.27 | 1.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.6% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $21.76 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.58 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.86 | 1.2% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $16.90 | 1.1% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $15.15 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,512.74 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $93.56 | 3 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $87.11 | 3 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $83.41 | 4 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $83.41 | 3 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.99 | 3 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.99 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $60.60 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $57.22 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $51.23 | 2 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $51.23 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $50.86 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $50.64 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $48.07 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $35.01 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $34.81 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $34.81 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $32.74 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| Gamifant Normalized: gamifant |
Drug | SOBI, INC | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 81 | 48 |
| Gabapentin | Gabapentin | 69 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 29 |
| Losartan Potassium | Losartan Potassium | 53 | 29 |
| Lisinopril | Lisinopril | 51 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | 20 |
| Metformin Hcl | Metformin Hcl | 44 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 15 |
| Ozempic | Semaglutide | 36 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 15 |
| Fluconazole | Fluconazole | 34 | 19 |
| Omeprazole | Omeprazole | 33 | 19 |
| Prednisone | Prednisone | 31 | 25 |
| Famotidine | Famotidine | 27 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 13 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 13 |
| Trazodone Hcl | Trazodone Hcl | 20 | 11 |
| Eliquis | Apixaban | 19 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Carvedilol | Carvedilol | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 15 | 11 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | 11 |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Spironolactone | Spironolactone | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,512.74 · 59 records | Janssen Biotech, Inc. | AKEEGA, Amtagvi, BALVERSA, CABOMETYX, CARVYKTI, DANZITEN, DARZALEX, ELAHERE, ELREXFIO, EPKINLY, ERLEADA, GIVLAARI, GOMEKLI, Gamifant, IBRANCE, IMBRUVICA, IMFINZI, INLYTA, JAKAFI, JEMPERLI, KEYTRUDA, KISQALI, LIBTAYO, LUPRON DEPOT, Lenvima, MI CANCER SEEK, MONJUVI, MONOFERRIC, NERLYNX, NIKTIMVO, Nubeqa, OGSIVEO, ORGOVYX, Orserdu, PADCEV, POTELIGEO, RYBREVANT, RYTELO, SCEMBLIX, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, TUKYSA, Vonjo, WAYRILZ, WELIREG, XTANDI, Xofigo, ZYNYZ, Zoladex, clonoSEQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error